Press releases
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
Geneva, Switzerland, 28 January 2025 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an additional four months, until May 27, 2025, under the continued supervision of a court-appointed commissary.
New data supporting a new precision medicine approach for ALS patients with GeNeuro’s GNK-301 presented at the 35th International Symposium on ALS/MND
Geneva, Switzerland, December 6, 2024 – 6:30 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-8, 2024. The presentation was delivered by Dr. Darshan Pandya, from National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH).
GeNeuro SA obtains the opening of debt-restructuring proceedings
Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.
GeNeuro announces that it submits a request for a debt moratorium to the Geneva Court of First Instance
Geneva, Switzerland, July 15, 2024 – 7:00 am CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the Geneva Court of First Instance a request for a debt moratorium to restructure its debts and find solutions for the continuity of its activities in the interests of all stakeholders
GeNeuro announces the results of the GNC-501 in post-COVID-19 syndrome
Geneva, Switzerland, June 28, 2024 – 7:00 am CEST – The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications.
GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting
GeNeuro Announces Approval of all Resolutions
Proposed at 2024 Annual General Meeting
Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of 12 June 2024.
/https://geneuro.ch/wp-content/uploads/GeNeuro_AGM_14062024-EN.pdf